Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA
A legfontosabb adatok
- Ki végzi
- University Health Network, Toronto
- Hol
- Toronto (Kanada)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 148 fő, tervezett
- Kezdés
- 2025. jan. 1.
- Várható befejezés
- 2028. dec.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation
- Saline (Placebo Comparator for BMA)
- Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations
- Saline (Placebo Comparator for LAM + LP-PRP)
- A regiszteradat frissítve
- 2026. augusztus 27.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with knee osteoarthritis (wear-and-tear arthritis) and lasting knee pain. It tests injections made from their own bone marrow, or their own fat plus blood, against salt-water injections.
- Életkor
- 30 years or older
- Nem
- Male or female
- A betegség stádiuma
- KL grade 2 or 3 knee osteoarthritis on a standing knee X-ray. Long-lasting knee pain in at least one knee, with a pain score (NPRS) of 4 points or more. Body mass index of 30 kg/m2 or less.
- Korábbi kezelés
- Cannot join after knee injections of corticosteroid, Synvisc, PRP or nSTRIDE-Autologous Protein Solution in the previous 6 months, or keyhole knee surgery in the previous 6 months. Cannot join after daily opioid use for the past 3 months, or long-term corticosteroid tablets or shots in the past 3 months.
A részvétel fő kizáró okai
- Other knee damage causing pain or swelling, such as ligament or meniscus injury, or a knee bent inward or outward by more than 10°
- Rheumatoid arthritis, gout, psoriatic arthritis or other inflammatory joint diseases
- Leukemia or other blood cancers, cancer that has spread, or ongoing or planned chemotherapy
- Hemophilia or other blood clotting disorders, or not able to stop anti-platelet medicines
- Weak immune system, active infection, or allergy to local anesthetics
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female at least 30 years of age at the time of screening
- Willingness and ability to comply with study procedures and visit schedules and able to follow oral and written instructions
- Signed consent for study participation
- Baseline NPRS ≥ 4 points
- Presence of chronic, symptomatic knee pain in at least one knee; if both knees are affected, the knee with greater severity will be selected for treatment
- KL grade 2 or 3 knee OA based on standing knee X-ray assessment
- Body mass index ≤ 30 kg/m2
Ki nem vehet részt
- Approved anti-inflammatory therapy injections (corticosteroid, Synvisc, PRP, nSTRIDE-Autologous Protein Solution) within the previous 6 months in the knee
- Any concomitant knee lesion causing pain or effusion (i.e., ligamentous or meniscal injury, osteochondral lesion)
- Arthroscopic knee surgery within the previous 6 months
- Presence of clinically observed active infection in the index knee
- Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; chondrocalcinosis, Paget's disease, or villonodular synovitis
- Diagnosed with leukemia or other hematologic cancers, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment
- A history of local anesthetic allergy
- Medical conditions such as hemophilia or other blood clotting disorders
- Use of systemic corticosteroids for treatment of a chronic medical condition within the past 3 months
- Daily opioid use for the past 3 months, use of non-steroidal anti-inflammatory drugs within 1 week of the procedure, unable to hold anti-platelet medications
- Major axial deviation (varus >10°, valgus >10°)
- Presence of venous or lymphatic stasis in the index leg
- Immunosuppression or acute infective processes; Study Treatment Exclusion:
- For Study 1: Inability to tolerate the bone marrow aspiration procedure resulting in insufficient collection of BMA (<10 mL) after two successive aspiration attempts
- For Study 2: Inability to tolerate the lipoaspiration procedure resulting in insufficient collection of LA (<40 mL) after two successive aspiration attempts
Helyszínek itt: Kanada
- Toronto Western Hospital, University Health NetworkToronto, KanadaContact: Shoba SinghRésztvevőt keres
- Women's College HospitalToronto, KanadaContact: Ananya PathakToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
ABLE OA is a Health Canada authorized (phase II/III) trial [Parent Control #: 263591]. A multi-center, prospective, double-blinded, randomized, placebo-controlled adaptive trial to evaluate the efficacy of two minimally manipulated autologous cellular preparations i) bone marrow aspirate (BMA) injection; and, ii) combined lipoaspirate micronized (LAM) and leukocyte poor (LP) platelet-rich plasma (PRP) injections for the treatment of knee osteoarthritis (OA).
A teljes eredeti leírásKevesebb
BMA, LAM from lipoaspirate (LA), and LP-PRP from whole blood will be prepared using the Cervos Marrow Cellution™ Bone Marrow Aspiration System, Cervos LIPO-PRO™ Adipose Transfer System, and Cervos KEYPRP Platelet Separator System, respectively.
Patient-reported outcome (PRO) measures will be collected using web- or paper-based questionnaires administered at baseline (pre-injection) as well as at 3, 6 and 12 months (post-injection). Blood, synovial fluid, and urine samples will be collected at baseline pre-injection and 6 months post-injection only.
A vizsgálat 4 csoportja
- For STUDY 1 (ARM A): Bone Marrow Aspirate (BMA)A vizsgált kezelés
This group will undergo a bone marrow aspiration and receive an ultrasound guided intra-articular injection of BMA (a single dose of cellular suspension of 9 mL or less)
Kezelés: Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation
- For STUDY 1 (ARM C): Saline InjectionPlacebo, összehasonlításként
This group will undergo a bone marrow aspiration and receive an ultrasound guided intra-articular injection of saline solution (9 mL)
Kezelés: Saline (Placebo Comparator for BMA)
- For STUDY 2 (ARM B): Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP)A vizsgált kezelés
This group will undergo a blood collection plus lipoaspiration and receive an ultrasound guided intra-articular injection of LAM (a single dose of cellular suspension of 9 mL or less) followed by LP-PRP (a single dose of cellular suspension of 2 mL or less)
Kezelés: Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations
- For STUDY 2 (ARM D): Saline InjectionPlacebo, összehasonlításként
This group will undergo a blood collection plus lipoaspiration and receive ultrasound guided intra-articular injections of saline solution (9 mL followed by 2 mL)
Kezelés: Saline (Placebo Comparator for LAM + LP-PRP)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Intra-Articular Autologous Bone Marrow Aspirate vs Placebo Injection and Lipoaspirate Micronized With Leukocyte-Poor Platelet Rich Plasma vs Placebo Injection Evaluations for Treatment of Knee OsteoArthritis: The ABLE OA Double-Blinded Randomized Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. augusztus 27.